BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 2.25 million shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-12-31 was 898.00K shares, a 33.53% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-09-30 was 184.00K shares, a 68.81% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-06-30 was 218.00K shares, a 91.23% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-03-31 was 917.00K shares, a 134.53% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 2.25M shares, a 1.40% increase from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 2.22M shares, a 12.82% increase from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 1.97M shares, a 40.04% decline from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 3.28M shares, a 102.66% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2016-12-31 | 2.25M shares 10-K · filed 2017-02-27 | |||
| 2015-12-31 | 898.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 1.08M shares derived: sum of 2 quarters · filed 2017-02-27 | 1.30M shares derived: sum of 3 quarters · filed 2017-02-27 | 2.22M shares 10-K · filed 2017-02-27 |
| 2015-09-30 | 184.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 402.00K shares derived: sum of 2 quarters · filed 2015-11-06 | 1.32M shares 10-Q · filed 2015-11-06 | 2.67M shares derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | 218.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 1.14M shares 10-Q · filed 2015-08-07 | 2.49M shares derived: sum of 3 quarters · filed 2017-02-27 | 2.60M shares derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | 917.00K shares 10-Q · filed 2015-05-08 | 2.27M shares derived: sum of 2 quarters · filed 2017-02-27 | 2.38M shares derived: sum of 3 quarters · filed 2017-02-27 | 2.49M shares derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | 1.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 1.46M shares derived: sum of 2 quarters · filed 2017-02-27 | 1.57M shares derived: sum of 3 quarters · filed 2017-02-27 | 1.97M shares 10-K · filed 2017-02-27 |
| 2014-09-30 | 109.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | 223.00K shares derived: sum of 2 quarters · filed 2014-11-07 | 614.00K shares 10-Q · filed 2014-11-07 | 654.00K shares derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | 114.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | 505.00K shares 10-Q · filed 2014-08-08 | 545.00K shares derived: sum of 3 quarters · filed 2016-02-26 | 1.78M shares derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | 391.00K shares 10-Q · filed 2014-05-09 | 431.00K shares derived: sum of 2 quarters · filed 2016-02-26 | 1.67M shares derived: sum of 3 quarters · filed 2016-02-26 | 1.77M shares derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | 40.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | 1.27M shares derived: sum of 2 quarters · filed 2016-02-26 | 1.38M shares derived: sum of 3 quarters · filed 2016-02-26 | 3.28M shares 10-K · filed 2016-02-26 |
| 2013-09-30 | 1.23M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | 1.34M shares derived: sum of 2 quarters · filed 2013-11-08 | 3.24M shares 10-Q · filed 2013-11-08 | 3.24M shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | 109.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | 2.00M shares 10-Q · filed 2013-08-08 | 2.00M shares derived: sum of 3 quarters · filed 2015-03-02 | 2.06M shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | 1.89M shares 10-Q · filed 2013-05-09 | 1.89M shares derived: sum of 2 quarters · filed 2015-03-02 | 1.95M shares derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 54.00K shares derived: sum of 2 quarters · filed 2015-03-02 | 1.62M shares 10-K · filed 2015-03-02 | |
| 2012-09-30 | 54.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | 1.62M shares 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | 1.56M shares 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | 1.83M shares 10-K · filed 2014-03-10 | |||
| 2010-12-31 | 1.55M shares 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |